Abstract
The strategy and SAR studies that led to the discovery of a novel potent and orally available 5-lipoxygenase (5-LO) inhibitor 3-(4-fluorophenyl)-6-({4-[(1S)-1-hydroxy-1-(trifluoromethyl)propyl]-1H-1,2,3-triazol-1-yl}methyl)-1-benzothiophene-2-carboxamide ((S)-2l or MK-5286) were described.
Copyright © 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Administration, Oral
-
Animals
-
Arachidonate 5-Lipoxygenase / chemistry*
-
Arachidonate 5-Lipoxygenase / metabolism
-
Dogs
-
Drug Evaluation, Preclinical
-
Humans
-
Hydrocarbons, Fluorinated / chemical synthesis
-
Hydrocarbons, Fluorinated / chemistry*
-
Hydrocarbons, Fluorinated / pharmacology
-
Lipoxygenase Inhibitors / chemical synthesis
-
Lipoxygenase Inhibitors / chemistry*
-
Lipoxygenase Inhibitors / pharmacokinetics
-
Rats
-
Structure-Activity Relationship
-
Thiophenes / chemical synthesis
-
Thiophenes / chemistry*
-
Thiophenes / pharmacology
-
Triazoles / chemical synthesis
-
Triazoles / chemistry*
-
Triazoles / pharmacology
Substances
-
Hydrocarbons, Fluorinated
-
Lipoxygenase Inhibitors
-
MK-5286
-
Thiophenes
-
Triazoles
-
benzothiophene
-
Arachidonate 5-Lipoxygenase